This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

Phase 1 Terminated 35 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compound's safety, the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells.

Timeline

Start: 2009-09
Primary completion: 2011-12
Completion: 2011-12

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Publications

Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Mol Cancer Ther. 2021 Oct;20(10):1836-1845. doi: 10.1158/1535-7163.MCT-20-1105. Epub 2021 Jul 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-03758309	Small molecule	1 mg	Oral